1. Drug Transport Mechanisms of Cancer Therapeutics Yan Shu Department of Pharmaceutical Sciences School of Pharmacy University of Maryland at Baltimore
2.
3. Signal Pathways in Determining Brian Tumor Permeability B2R: bradykinin receptor 2; NOS: nitric oxide synthase; sGC: soluble guanylate cyclase; PKG: cGMP-dependent protein kinase; PDE5: phosphodiesterase type 5 sGC Calmodulin NOS PKG K Ca Channel [Ca 2+ ]i [cGMP] PDE5 [NO] 5’GMP IBTX, CTX, TEA NS1619, NS004 L-Arg L-Cit HOE140 Levitra, Viagra, Zaprinast Rp-8BR-cGMP Brain Tumor permeability B2R Bradykinin L-NMMA 2-APB ? LY83583
4. Modulation of Brain Tumor Permeability by PDE5 Inhibitors Tumor Permeability Survival Tumor Size BK: bradykinin; SIL:sildenafil; VAR: vardenafil; TAD: tadalafil Black et al, Brain Res 2008
5. Increased Vesicle Formation in Brain Tumors by Vardenafil (Levitra) a, Normal tissue/PBS; b, Tumor tissue/PBS c. Tumor tissue/Levitra 1 hour; d, Tumor tissue/Levitra 2 hours; e, Tumor tissue/Levitra 3 hours
6. Modulation of Brain Tumor Permeability by NO Donors in Rats Bearing Brain Tumors Yin et al, Clin Cancer Res 2008
12. Cisplatin-responsive and –resistant Human Cervical Cancer Cells OCT3 expression in KB-3-1 and KB-CP20 cells 2D-Gel shows differences in protein expression between KB-3-1 and KB-CP20 cells KB-3-1 KB-CP20
13. Qing Li, MD, PhD Cedars-Sinai Medical Center, Los Angeles Keith L. Black, MD Dali Yin, MD Jinwei Hu, MD Bindu Konda, MS Andres Espinoza, MD Acknowledgement